GSK is staking billions on a new way to protect people from life‑threatening food allergies, agreeing to buy RAPT ...

GlaxoSmithKline (GSK) has agreed to acquire Rapt Therapeutics for $2.2 billion, the companies said today, in a deal intended to bolster the buyer’s pipeline with Rapt’s ozureprubart (RPT904), a ...

RAPT Therapeutics, Inc. is being acquired by GSK plc for $2.2B as ozureprubart targets IgE disorders with 8–12 week dosing.

Jan 20 (Reuters) - Britain's GSK has agreed to ‌buy ​RAPT Therapeutics for $2.2 billion, accessing the U.S. biotech's ...

The deal is the first for new CEO Luke Miels as the British drugmaker looks to overcome pressure on its HIV and vaccines ...

RAPT Therapeutics shares surged after GSK agreed to acquire the biotech for $2.2 billion, adding a promising food allergy ...

GSK signed an agreement to acquire RAPT Therapeutics for around $2.2 billion. ・The deal centers on an experimental allergy ...

GSK said Tuesday that it made a deal to pay RAPT shareholders $58 per share, with $1.9 billion upfront investment in cash. The acquisition is expected to close in the first quarter of 2026 with an ...

Dr. Geetika Sabharwal has been honored with a 2025 Global Recognition Award for her sustained contributions to allergy and ...

Drug-induced fever can complicate antibiotic treatment and lead to unnecessary testing when cultures are negative, and ...

Patients who start their blood pressure treatment with ARB drugs continue with the same medicine to a greater extent than patients who start out with other drugs. Choosing the right drug from the ...